Muvalaplin, a drug under development at Eli Lilly, lowered lipoprotein levels by 65 percent, according to results published Aug. 28 in JAMA.
The medication could be the first treatment for lipoprotein, a genetic marker of cholesterol that increases the risk of heart attack and stroke. Lipoprotein is stickier than LDL cholesterol, and drugs indicated for LDL aren’t as effective for lipoprotein, meaning muvalaplin has potential to be the first drug to tackle “sticky” cholesterol.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
